Dr. Jonathan Li is the Director of the Harvard/Brigham Virology Specialty Laboratory, the Director of the Harvard University Center for AIDS Research Clinical Core, a member of the AIDS Clinical Trials Group Executive Committee, and a member of the NIH COVID-19 Treatment Guidelines Panel. His research is focused on HIV and SARS-CoV-2 drug resistance, reservoirs, and viral remission. He is active in the AIDS Clinical Trials Group (ACTG) as a member of the ACTG HIV Reservoirs and Viral Eradication Transformative Science Group and as the Chair of several ACTG clinical trials. He is the Deputy Editor of the IDSA journal Open Forum Infectious Diseases and the Editorial Advisory Board of the Journal of Infectious Diseases. In addition, he sees patients in both the outpatient Infectious Diseases clinic and in the inpatient consult service at the Brigham and Women’s Hospital.
Current research projects include:
- Predictors of HIV rebound after treatment interruption and post-treatment virologic control
- Impact of HIV minority variants using next-generation sequencing
- HIV integration into the human genome
- Mechanisms and clinical impact of persistent low-level HIV viremia despite antiretroviral therapy
- Clinical and translational research in coronaviruses and COVID-19 disease
The Li Laboratory is located in Cambridge MA, and is associated with Brigham and Women’s Hospital and Harvard Medical School.